EUVIMEDEUVIMED entdecken
Crossref

Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer

Dianhui Wei, Lili Yuan, Xiaoli Xu, Chengsi Wu, Yiwen Huang, Lili Zhang, Jilong Zhang, Tiantian Jing, Yizhen Liu, Boshi Wang

Cancer Letters · 2024-11 · 605 · 217284

DOI: 10.1016/j.canlet.2024.217284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-11. Verfasst von Dianhui Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, Drug Resistance, Neoplasm, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Shanghai Municipal Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemoresistance remains a formidable challenge in pancreatic ductal adenocarcinoma (PDAC) treatment, necessitating a comprehensive exploration of underlying molecular mechanisms. This work aims to investigate the dynamic epigenetic landscape during the development of gemcitabine resistance in PDAC, with a specific focus on super-enhancers and their regulatory effects. We employed well-established gemcitabine-resistant (Gem-R) PDAC cell lines to perform high-throughput analyses of the epigenome, enhancer connectome, and transcriptome. Our findings revealed notable alterations in the epigenetic landscape and genome architecture during the transition from gemcitabine-sensitive to -resistant PDAC cells. Remarkably, we observed substantial plasticity in the activation status of super-enhancers, with a considerable proportion of these cis-elements becoming deactivated in chemo-resistant cells. Furthermore, we pinpointed the NDRG1 super-enhancer (NDRG1-SE) as a crucial regulator in gemcitabine resistance among the loss-of-function super-enhancers. NDRG1-SE deactivation induced activation of WNT/β-catenin signaling, thereby conferring gemcitabine resistance. This work underscores a NDRG1 super-enhancer deactivation-driven β-catenin pathway activation as a crucial regulator in the acquisition of gemcitabine-resistance. These findings advance our understanding of PDAC biology and provide valuable insights for the development of effective therapeutic approaches against chemoresistance in this malignant disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineDeoxycytidineDrug Resistance, NeoplasmPancreatic NeoplasmsEpigenesis, GeneticIntracellular Signaling Peptides and ProteinsCell Cycle Proteinsbeta CateninCarcinoma, Pancreatic DuctalGene Expression Regulation, NeoplasticHumansCell Line, TumorAntimetabolites, AntineoplasticEnhancer Elements, GeneticWnt Signaling PathwayN-myc Downstream-Regulated Gene 1 Protein

Stichwörter der Autor:innen

Dynamic epigenetic landscapeGemcitabine resistancePancreatic ductal adenocarcinoma (PDAC)Super-enhancer

Substanzen

GemcitabineDeoxycytidineIntracellular Signaling Peptides and ProteinsCell Cycle Proteinsbeta CateninAntimetabolites, AntineoplasticN-myc Downstream-Regulated Gene 1 ProteinCTNNB1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.
  • Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun, 130023, China. Electronic address: jilongzhang@jlu.edu.cn.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China. Electronic address: jingtiantian1991@126.com.
  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. Electronic address: aliuyz@126.com.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China. Electronic address: wbs137@shsci.org.

Förderung

  • Shanghai Municipal Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Wei, D., Yuan, L., Xu, X., Wu, C., Huang, Y., Zhang, L., Zhang, J., Jing, T., Liu, Y., & Wang, B. (2024). Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer. Cancer Letters, 605, 217284. https://doi.org/10.1016/j.canlet.2024.217284

Vancouver

Wei D, Yuan L, Xu X, Wu C, Huang Y, Zhang L, et al. Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer. Cancer Letters. 2024;605:217284. doi:10.1016/j.canlet.2024.217284

BibTeX
@article{Wei2024,
  author = {Wei, Dianhui and Yuan, Lili and Xu, Xiaoli and Wu, Chengsi and Huang, Yiwen and Zhang, Lili and Zhang, Jilong and Jing, Tiantian and Liu, Yizhen and Wang, Boshi},
  title = {Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer},
  journal = {Cancer Letters},
  year = {2024},
  volume = {605},
  pages = {217284},
  doi = {10.1016/j.canlet.2024.217284}
}
Kostenlos starten →